盐酸多柔比星脂质体注射剂Caelyx Injection 20mg

药店国别： 产地国家：欧洲共同体国家 处方药：是 所属类别： 20毫克/10毫升/瓶 包装规格： 20毫克/10毫升/瓶 计价单位：瓶 生产厂家中文参考译名： 生产厂家英文名：Ben Venue Laboratories, Inc. 原产地英文商品名：Caelyx 20mg/10ml/bottle 原产地英文药品名：Pegylated liposomal doxorubicin hydrochloride 中文参考商品译名：楷莱注射液 20毫克/10毫升/瓶 中文参考药品译名：盐酸多柔比星脂质体 曾用名： 简介：部份中文盐酸多柔比星脂质体处方资料(仅供参考)药品名：盐酸多柔比星脂质体注射液英文名：Pegylated liposomal doxorubicin hydrochloride商品名：楷莱(Caelyx)生产商：Ben Venue Laboratories, Inc.性状：脂质体制剂 适应症： 用于低CD4(<200 CD4淋巴细胞/mm3)及有广泛皮肤粘膜内脏疾病的与艾滋病相关的卡波氏肉瘤(AIDS-KS)病人。规格：20mg/10ml药物介绍本品是一种脂质体制剂，系将盐酸多柔比星通过与甲氧基聚乙二醇的表面结合包封于脂质体中。这种工艺被称作为空间稳定或隐匿，可以保护脂质体免受单核巨噬细胞系统(MPS)识别，从而延长其在血液循环中的时间。　　可用作一线全身化疗药物，或者用作治疗病情有进展的AIDS-KS病人的二线化疗药物，也可用于不能耐受下述两种以上药物联合化疗的病人：长春新碱、博莱霉素和多柔比星(或其他蒽环类抗生素)。 盐酸多柔比星脂质体注射剂 Zydus Cadila has introduced an NDDS product 'Nudoxa' for the treatment of various cancers.One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach in cancer therapy.With chemotherapy being a common mode of treatment in cancers, there has been a long standing need for a drug that is stable and long lasting with reduced toxicity and side effects. Nudoxa addresses this need. A patented product in India and South Africa, patents for Nudoxa have also been filed in EU, US, Japan and several countries globally.Doxorubicin, the first generation drug, was launched in 1960s and gave a new lease of life to cancer patients with its ability to combat aggressive and malignant tumours. This DNA-interacting drug, however, was discovered to cause life-threatening side effects in the form of cardiac abnormalities.An advancement on this therapy resulted in liposomal doxorubicin in which the molecules of the drug are encapsulated in a fatty coating known as liposomes. The liposomes allow the doxorubicin to be delivered specifically in greater amounts to the cancer cells, while having fewer side effects on the healthy tissues.A further advancement in this line of treatment was the Pegylated-liposomaldoxorubicin, a unique form of liposomal doxorubicin in which the liposomes are coated with polyethylene glycol, leading to a much longer half-life in the blood.However Pegylated-liposomal doxorubicin are likely to cause ‘Hand-Foot Syndrome,' characterized by skin eruptions on the palms of the hand or soles of the feet, leading to interruption in therapy.A new variant of liposomal doxorubicin, Nudoxa with its unique drug delivery system is a breakthrough in cancer therapy as it offers the benefits of Pegylated-liposomal doxorubicin without its major side effects like the Hand Foot syndrome.Marketed by Zydus Biogen, Nudoxa is manufactured by Zydus-BSV Pharma Pvt. Ltd., the joint venture company of Zydus Cadila and Bharat Serums and Vaccines Pvt.Ltd. Founded in 2005, Zydus-BSV Pharma focuses on targeted therapies in the area of Oncology.Nudoxa is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer - the second most common type of cancer, ovarian cancer - the fifthleading cause of cancer death in women, and AIDS-related Kaposi sarcoma which develops in people who are infected with the human immunodeficiency virus (HIV).